CYP2C8/9/18/19 Polyclonal antibody
CYP2C8/9/18/19 Polyclonal Antibody for WB, IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
WB, IHC, ELISA
Conjugate
Unconjugated
Cat no : 16546-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | mouse liver tissue, rat liver tissue |
Positive IHC detected in | human liver cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:2000-1:10000 |
Immunohistochemistry (IHC) | IHC : 1:300-1:1200 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
WB | See 12 publications below |
IHC | See 8 publications below |
Product Information
16546-1-AP targets CYP2C8/9/18/19 in WB, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.
Tested Reactivity | human, mouse, rat |
Cited Reactivity | human, mouse, rat |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | CYP2C8/9/18/19 fusion protein Ag9898 |
Full Name | cytochrome P450, family 2, subfamily C, polypeptide 8 |
Calculated Molecular Weight | 490 aa, 56 kDa |
Observed Molecular Weight | 50 kDa |
GenBank Accession Number | BC020596 |
Gene Symbol | CYP2C8 |
Gene ID (NCBI) | 1558 |
RRID | AB_2089685 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
CYP2C8(Cytochrome P450 2C8) is also named as CYPIIC8, cytochrome P450 IIC2, cytochrome P450 MP-12, cytochrome P450 MP-20, cytochrome P450 form 1 and S-mephenytoin 4-hydroxylase. It belongs to the cytochrome P450 family. It is a monooxygenase involved in an NADPH-dependent electron transport pathway and a hepatic drug-metabolizing enzymes that oxidizes therapeutic drugs such as cerivastatin and endobiotics such as retinoic acid and arachidonic acid. It has 2 isoforms produced by alternative splicing. This antibody can recognize human CYP2C 8/9/18/19, mouse CYP2C 29/37/38/39/55/65/, rat CYP2C6/7/11/12/13/23 due to the high homology.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for CYP2C8/9/18/19 antibody 16546-1-AP | Download protocol |
IHC protocol for CYP2C8/9/18/19 antibody 16546-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
Cell Chem Biol 3D two-photon brain imaging reveals dihydroartemisinin exerts antiepileptic effects by modulating iron homeostasis. | ||
Front Oncol Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer. | ||
Front Oncol Novel Prognostic Signatures of Hepatocellular Carcinoma Based on Metabolic Pathway Phenotypes. | ||
Pharmaceutics Assessing CYP2C8-Mediated Pharmaceutical Excipient-Drug Interaction Potential: A Case Study of Tween 80 and Cremophor EL-35. | ||
Front Pharmacol Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology. | ||
BMC Cancer Elevated 14,15- epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. |